What is the difference between complete response and stringent complete response?

FAQ Library published on March 4, 2013 in Response Assessment, General Education
Download Transcript Download Audio
Rafael Fonseca, MD
Deputy Director, Mayo Clinic Cancer Center
Getz Family Professor of Cancer
Professor of Medicine, Mayo Clinic College of Medicine
Site Director, Hematological Malignancies, Mayo Clinic
Scottsdale, Arizona

Hi, my name is Rafael Fonseca, I am a professor medicine at the Mayo Clinic in Arizona. I am frequently asked to define a complete response and a stringent complete response both in the setting of clinical trials as well as standard clinical practice. Complete response remains as it has always been, it is our patients who achieve a negative immunofixation on the serum and urine and who also have an appearance of a soft tissue plasmacytomas and achieve less than or equal to 5% plasma cells in the bone marrow. In the latest criteria, however, we introduce the objective of a stringent complete response, and this is one that takes into consideration now more sensitive methods for the detection of monoclonal plasma cells. Patients with a stringent complete response in addition to the criteria that is required to have a complete response are required to have a normal free light chain ratio in the serum and absence of clonal cells in the bone marrow determined by either immunofluorescence or immunohistochemistry.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Category
How can you ensure patients are reporting side effects?
FAQ Library published on May 9, 2013 in Response Assessment, Comorbidities/SEs
What is 'stable disease' in multiple myeloma?
FAQ Library published on March 6, 2013 in Response Assessment, General Education
What constitutes a very good partial response in multiple myeloma?
FAQ Library published on March 6, 2013 in Response Assessment, General Education
When do I refer a relapsed/refractory patient to a clinical trial?
FAQ Library published on February 9, 2012 in General Education, Patient Communication, Nurses & Pharmacists, Clinical Trials
What are effective ways to ensure patient compliance?
FAQ Library published on April 20, 2011 in General Education, Patient Communication, Patient Education, Nurses & Pharmacists
Is there a role for multidisciplinary care in the treatment of multiple myeloma?
FAQ Library published on December 9, 2009 in General Education
What is the important endpoint to look for in multiple myeloma studies?
FAQ Library published on July 22, 2009 in Response Assessment
Related Items by Author
What is 'stable disease' in multiple myeloma?
Rafael Fonseca, MD
FAQ Library published on March 6, 2013 in Response Assessment, General Education
What constitutes a very good partial response in multiple myeloma?
Rafael Fonseca, MD
FAQ Library published on March 6, 2013 in Response Assessment, General Education